Abstract
Crohn’s disease is a chronic lifelong disease, to which there is currently no medical cure. However, effective immunosuppressive therapy has become the mainstay of inducing and maintaining remission in IBD patients. It is often during the maintenance phase of treatment, when patients are feeling well, that consideration or inquisition is made to stopping or reducing immunosuppression. This chapter outlines the evidence describing the risks of disease relapse in patients that reduce or stop medical therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95.
Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392–400.
Yarur AJ, Kubiliun MJ, Czul F, Sussman DA, Quintero MA, Drake KA, Hauenstein SI, Lockton S, Deshpande AR, Barkin JS, Singh S, Abreu MT, Jain A. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol. 2015. doi:10.1016/j.cgh.2014.12.026.
Vande Casteele N, Compernolle G, Ballet V, et al. Individualised infliximab treatment using therapeutic drug monitoring: a prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial. J Crohns Colitis. 2012;6(Suppl):S6.
Baert F, Glorieus E, Reenaers C, et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn’s patients. J Crohns Colitis. 2013;7:154–60.
Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992;305:20–2.
Cassinotti A, Actis GC, Duca P, et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol. 2009;104:2760–7.
Lémann M, Mary J-Y, Colombel J-F, et al. A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine. Gastroenterology. 2005;128:1812–8.
French H, Mark Dalzell A, Srinivasan R, El-Matary W. Relapse rate following azathioprine withdrawal in maintaining remission for Crohn’s disease: a meta-analysis. Dig Dis Sci. 2011;56:1929–36.
Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–9.
Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.
Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134:1861–8.
Oussalah A, Chevaux J-B, Fay R, Sandborn WJ, Bigard M-A, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn’s disease treated with combination therapy. Am J Gastroenterol. 2010;105:1142–9.
Lémann M, Mary J-Y, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology. 2006;130:1054–61.
Costes L, Colombel JF, Mary JY, et al. Long term follow-up of a cohort of steroid-dependent Crohn’s disease patients included in a randomized trial evaluating short term infliximab combined with Azathioprine. Gastroenterology. 2008;134 Suppl 1:A134.
Louis E, Mary J-Y, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142:63–70.
Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Østergaard Thomsen O, Seidelin JB. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol. 2012;47:518–27.
Waugh AWG, Garg S, Matic K, et al. Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharmacol Ther. 2010;32:1129–34.
Molnár T, Lakatos PL, Farkas K, et al. Predictors of relapse in patients with Crohn’s disease in remission after 1 year of biological therapy. Aliment Pharmacol Ther. 2013;37:225–33.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Stein, D.J. (2015). Can I Stop My Medications Now that I Am Feeling Well? Why Maintenance Therapy Is Important in Preventing Recurrence in Crohn’s Disease. In: Stein, D., Shaker, R. (eds) Inflammatory Bowel Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-14072-8_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-14072-8_12
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-14071-1
Online ISBN: 978-3-319-14072-8
eBook Packages: MedicineMedicine (R0)